Molecular pathogenesis of non muscle-invasive bladder cancer: Implications for novel targeted therapies

Current Molecular Medicine

Volumn 11, Issue 8, 2011, Pages 623-632

  Zachos, I ^a   Tzortzis, V ^a   Konstantinopoulos, P A ^b,c   Karatzas, A ^a   Gravas, S ^a   Melekos, M ^a   Papavassiliou, A G ^c  

^a UNIVERSITY OF THESSALY   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bladder cancer; Molecular pathogenesis; Non muscle invasive disease; PI3K AKT pathway; RASMAPK pathway; Targeted therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCG VACCINE; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; GEMCITABINE; GREEN TEA EXTRACT; HALOFUGINONE; HEAT SHOCK PROTEIN 27; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R3; OGX 42; OGX 427; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PRO 001; PROTEIN KINASE B; PROTEIN PATCHED 1; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER RECURRENCE; CARCINOMA IN SITU; CHROMOSOME 9P; CHROMOSOME 9Q; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; ONCOGENE H RAS; ONCOGENE RAS; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL TRANSFORMATION, NEOPLASTIC; GENE DELETION; HUMANS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SIGNAL TRANSDUCTION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 80053937661     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411797536697     Document Type: Review

References (98)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59(4): 225-49.
2. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 1992; 19(3): 429-33.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49(3): 466-5; discussion 75-7.
4. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004; 171(6 Pt 1): 2186-90, quiz 435.
5. Sylvester RJ, Oosterlinck W, Witjes JA. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol 2008; 53(4): 709-19.
6. Babjuk M. New insights in intravesical treatment for intermediate- and high-risk non-muscle-invasive urothelial bladder carcinoma. Eur Urol; 57(5): 774-6; author reply 6-7.
7. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163(4): 1124-9.
8. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006; 27(3): 361-73.
9. Bakkar AA, Wallerand H, Radvanyi F, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003; 63(23): 8108-12.
10. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005; 304(2): 417-31.
11. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005; 24(33): 5218-25.
12. Rieger-Christ KM, Mourtzinos A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer 2003; 98(4): 737-44.
13. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol 2001; 158(6): 1955-9.
14. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene 2001; 20(6): 686-91.
15. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97(3): 729-36.
16. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007; 213(1): 91-8.
17. Paterson JL, Li Z, Wen XY, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 2004; 124(5): 595-603.
18. Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 2009; 69(11): 4613-20.
19. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer; 104(1): 75-82.
20. Hernandez S, Lopez-Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 2006; 24(22): 3664-71.
21. Lopez-Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006; 66(15): 7401-4.
22. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001; 61(4): 1265-8.
23. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006; 33(4): 407-20.
24. Knowles MA, Williamson M. Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphism analysis, designed restriction fragment length polymorphisms, and direct sequencing. Cancer Res 1993; 53(1): 133-9.
25. Zhang ZT, Pak J, Huang HY, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001; 20(16): 1973-80.
26. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene 1999; 18(16): 2657-61.
27. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999; 80(5-6): 904-8.
28. Cairns P, Evron E, Okami K, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998; 16(24): 3215-8.
29. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009; 23(6): 675-80.
30. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16(4): 525-37.
31. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27(13): 2278-87.
32. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009; 73(3): 665-8; discussion 8-9.
33. Seager CM, Puzio-Kuter AM, Patel T, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila) 2009; 2(12): 1008-14.
34. Rosner M, Hanneder M, Siegel N, Valli A, Fuchs C, Hengstschlager M. The mTOR pathway and its role in human genetic diseases. Mutat Res 2008; 659(3): 284-92.
35. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009; 8(24): 2339-47.
36. Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA, Santos L. Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res 2009; 28: 3.
37. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005; 96(1): 7-12.
38. Williamson MP, Elder PA, Shaw ME, Devlin J, Knowles MA. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 1995; 4(9): 1569-77.
39. Florl AR, Franke KH, Niederacher D, Gerharz CD, Seifert HH, Schulz WA. DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest 2000; 80(10): 1513-22.
40. Chow NH, Cairns P, Eisenberger CF, et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000; 89(6): 514-8.
41. McGarvey TW, Maruta Y, Tomaszewski JE, Linnenbach AJ, Malkowicz SB. PTCH gene mutations in invasive transitional cell carcinoma of the bladder. Oncogene 1998; 17(9): 1167-72.
42. Habuchi T, Luscombe M, Elder PA, Knowles MA. Structure and methylation-based silencing of a gene (DBCCR1) within a candidate bladder cancer tumor suppressor region at 9q32-q33. Genomics 1998; 48(3): 277-88.
43. Louhelainen JP, Hurst CD, Pitt E, Nishiyama H, Pickett HA, Knowles MA. DBC1 re-expression alters the expression of multiple components of the plasminogen pathway. Oncogene 2006; 25(16): 2409-19.
44. Cordon-Cardo C. Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl 2008; (218): 154-65.
45. Orlow I, Lacombe L, Hannon GJ, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995; 87(20): 1524-9.
46. Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003; 9(1): 235-42.
47. Chang LL, Yeh WT, Yang SY, Wu WJ, Huang CH. Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol 2003; 170(2 Pt 1): 595-600.
48. Kawamoto K, Enokida H, Gotanda T, et al. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer. Biochem Biophys Res Commun 2006; 339(3): 790-6.
49. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160(3 Pt 1): 645-59.
50. Crew JP, O'Brien TS, Harris AL. Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target. Cancer Metastasis Rev 1996; 15(2): 221-30.
51. Fauconnet S, Bernardini S, Lascombe I, et al. Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol Rep 2009; 21(6): 1495-504.
52. Crew JP, O'Brien T, Bradburn M, et al. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57(23): 5281-5.
53. Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D, Harris AL. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 1999; 161(3): 799-804.
54. Slaton JW, Millikan R, Inoue K, et al. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol 2004; 171(2 Pt 1): 570-4.
55. Birkhahn M, Mitra AP, Williams AJ, et al. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol; 57(1): 12-20.
56. Rajkumar T, Stamp GW, Pandha HS, Waxman J, Gullick WJ. Expression of the type 1 tyrosine kinase growth factor receptors EGF receptor, c-erbB2 and c-erbB3 in bladder cancer. J Pathol 1996; 179(4): 381-5.
57. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006; 12(15): 4671-7.
58. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 2004; 10(14): 4874-84.
59. Kassouf W, Dinney CP, Brown G, et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 2005; 65(22): 10524-35.
60. Kassouf W, Black PC, Tuziak T, et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008; 179(1): 353-8.
61. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7(7): 1957-62.
62. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79(4): 1283-316.
63. Williams LT. Signal transduction by the platelet-derived growth factor receptor. Science 1989; 243(4898): 1564-70.
64. Mizutani Y, Okada Y, Yoshida O. Expression of plateletderived endothelial cell growth factor in bladder carcinoma. Cancer 1997; 79(6): 1190-4.
65. Li N, Kanda K, Fukumori T, et al. Expression of vascular endothelial growth factor isoforms and platelet-derived endothelial cell growth factor in bladder cancer. Urol Oncol 2000; 6(1): 10-5.
66. Li S, Nomata K, Sawase K, Noguchi M, Kanda S, Kanetake H. Prognostic significance of platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in stage pT1 G3 bladder cancer. Int J Urol 2001; 8(9): 478-82.
67. Black PC, Brown GA, Dinney CP, et al. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol; 185(2): 693-700.
68. Konstantinopoulos PA, Karamouzis MV, Papatsoris AG, Papavassiliou AG. Matrix metalloproteinase inhibitors as anticancer agents. Int J Biochem Cell Biol 2008; 40(6-7): 1156-68.
69. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 1999; 161(4): 1359-63.
70. Papathoma AS, Petraki C, Grigorakis A, et al. Prognostic significance of matrix metalloproteinases 2 and 9 in bladder cancer. Anticancer Res 2000; 20(3B): 2009-13.
71. Elkin M, Ariel I, Miao HQ, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999; 59(16): 4111-8.
72. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15(1): 61-75.
73. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005 Summer; 10(2): 86-103.
74. Kapranos N, Kominea A, Konstantinopoulos PA, et al. Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002; 128(8): 426-32.
75. van de Vijver MJ, He YD, van't Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347(25): 1999-2009.
76. Takashi M, Katsuno S, Sakata T, Ohshima S, Kato K. Different concentrations of two small stress proteins, alphaB crystallin and HSP27 in human urological tumor tissues. Urol Res 1998; 26(6): 395-9.
77. Matsui Y, Hadaschik BA, Fazli L, Andersen RJ, Gleave ME, So AI. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer. Mol Cancer Ther 2009; 8(8): 2402-11.
78. Kamada M, So A, Muramaki M, Rocchi P, Beraldi E, Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6(1): 299-308.
79. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004; 64(18): 6595-602.
80. Hadaschik BA, Jackson J, Fazli L, et al. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. BJU Int 2008; 102(5): 610-6.
81. Qing J, Du X, Chen Y, et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009; 119(5): 1216-29.
82. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006; 107(10): 4039-46.
83. Makhlin I, Zhang J, Long CJ, et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011; 108: E84-90.
84. NCT01259063 C. RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder 2010.
85. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6(12): 4874-84.
86. Jin Y, Iwata KK, Belldegrun A, et al. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther 2006; 5(7): 1754-63.
87. Zachos I, Konstantinopoulos PA, Tzortzis V, et al. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 2010; 19(7): 875-87.
88. Sonpavde G, Sternberg CN. Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. BJU Int 2008; 102(9 Pt B): 1354-60.
89. NCT00352079. Title BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer 2010.
90. NC0008946 C. Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer December 2009.
91. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007; 6(7): 541-55.
92. Kohl NE, Mosser SD, deSolms SJ, et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260(5116): 1934-7.
93. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22(8): 1430-8.
94. Eric Winquist MJM KC SE, Hal Hirte, Neil Iscoe. NCIC CTG IND.128: a Phase II Study of a Farnesyl Transferase Inhibitor (SCH 66336) in Patients with Unresectable or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Failing Prior Chemotherapy. ASCO Annual Meeting 2001.
95. NCT00006351 C. Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract.
96. NCT01118351 C. Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer. 2010.
97. NCT00794950 C. Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma (Sutent). 2010.
98. NCT00959868 C. A Study for Treatment of Superficial Bladder Cancer Using OGX-427.